Skip to main content

Lymphoma, Large B-Cell, Diffuse Expanded Access For Subjects Receiving Lisocabtagen Maraleucel JCAR017-EAP-001

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Berkeley
  • Sacramento

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release (JCAR017-EAP-001)

Oleg I Krijanovski, M.D., Ph.D.
Oleg I Krijanovski, M.D., Ph.D.
Principal investigator
View profile
Elias Nicolas Kiwan, M.D.
Elias Nicolas Kiwan, M.D.
Principal investigator
View profile

Sub-Investigator

Kevin B Knopf, M.D., MPH

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Large B-Cell Lymphoma Alpha3

    A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma

    Status: Open to Enrollment

  • Clinical trial

    Neoadjuvant Lymphoma DLBCL waveLINE-010

    A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) MK-2140-010

    Status: Open to Enrollment

  • Clinical trial

    Interventional Myeloma EQUATE EAA181

    Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

    Status: Open to Enrollment

  • Clinical trial

    Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006

    Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma

    Status: Open to Enrollment

  • Clinical trial

    Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001

    Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

    Status: Coming Soon

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?